Abstract
Moderate-to-severe mitral regurgitation (MR) is present in up to 10% of patients with cardiogenic shock (CS). Patients with CS and concomitant MR have a guarded prognosis with conventional medical therapy alone. The purpose of this study was to explore outcomes of MitraClip device repair of severe MR in this high-risk patient population with shock.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Society for Cardiovascular Angiography & Interventions
Paper Title
Journal
Date
